Their second lead asset is a wholly owned monoclonal antibody Pamrevlumab (FG-3019) directed against CTGF, a growth factor involved in fibrogenesis. Neutralizing this factor has shown promise in multiple preclinical models of fibrosis and in an open label Ph1 study in patients with IPF, a type of fibrosis in the lung. In that clinical study, patients saw a decline in the rate of progression (as measured by Forced Vital Capacity and High Resolution Computed Tomography) on par with both Nintedanib and Pirfenidone, the two competitors on the market. Moreover, in ~25% of patients there was an improvement in lung function, arguably making it the first drug capable of reversing fibrosis in humans. IPF affects around 100K people in the US and sales of IPF drugs are projected to exceed $1B by 2020. FibroGen has now fully enrolled a placebo-controlled Ph2 study with expected results in summer 2017. They will also be including a 6-month sub-study evaluating the efficacy of FG-3019 as a companion product with the standard of care. Data for this study is also expected in summer 2017.

FibroGen Set Up For A Big Year
Phase 1/2 data for unresectable pancreatic cancer in January. Phase 3 data for Chronic Kidney Disease in 1Q17. Phase 2 data for Idiopathic Pulmonary Fibrosis in
More info @
Automated post from PF Warrior –
January 26, 2017 at 07:27AM